GlassScriptPhysician profile
Matthew M Dee
NPI 1134772379
$11,886.81
in general payments reported to CMS, 2019-2025
29 companies · $2,746 in 2025
The $2,746 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,076 · 2022: $1,961 · 2023: $2,156 · 2024: $2,948 · 2025: $2,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,656 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,656.27 |
| Education | $193.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,777.83 | 2021-2025 | |
| Janssen Biotech, INC. | $1,510.53 | 2021-2025 | Tremfya, Stelara, Simponi |
| Ucb, INC. | $1,008.28 | 2021-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $956.67 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $910.11 | 2021-2025 | |
| Pfizer INC. | $877.57 | 2021-2025 | |
| Lilly USA, LLC | $804.31 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $619.51 | 2021-2025 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $602.35 | 2022-2024 | Sotyktu |
| Amgen INC. | $438.48 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $358.61 | 2021-2025 | Dupixent |
| Galderma Laboratories, L.P. | $293.46 | 2021-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $255.05 | 2021-2025 | Adbry |
| Genzyme Corporation | $249.48 | 2021-2025 | |
| Dermavant Sciences, INC. | $212.88 | 2023-2024 | Vtama |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $212.55 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.14 | 2022-2025 | Spevigo, Cyltezo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $144.67 | 2021-2025 | Jublia, Cabtreo, Arazlo |
| Vyne Pharmaceuticals INC. | $140.75 | 2021 | |
| Organon LLC | $72.74 | 2025 | Nexplanon, Vtama |
| Blueprint Medicines Corporation | $46.50 | 2025 | Ayvakit |
| Dermira, INC. | $41.12 | 2021 | |
| Biofrontera INC. | $34.42 | 2021 | |
| Mimedx Group, INC. | $22.28 | 2024 | |
| Merz North America, INC. | $22.20 | 2024 | |
| Botanix Sb INC | $20.94 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $19.90 | 2023 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $14.51 | 2023 | Valchlor |
| Kyowa Kirin, INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Dee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.